The Central Illinois Community Clinical Oncology Program (CICCOP) brings clinical trials of high scientific validity to people living in 37 counties in Central, Southern and Northeast Illinois. The service area includes 2,262,917 people living in 20,936 square miles, 19.8 percent of the populations and 37.7 percent of the land in Illinois. The CICCOP has contributed 1931 protocol entries since it was founded in 1987. The CICCOP goal is to reduce cancer incidence, morbidity and mortality by accelerating the transfer of newly developed technology to widespread community application.
The specific aims are to: 1) Successfully implement National Cancer Institute (NCI) sponsored prevention and control protocols to persons living in 37 Illinois counties. 2) Successfully implement NCI sponsored cancer treatment protocols for patients with cancer living in 37 Illinois counties. 3) Benefit the care of patients and participants by collaborating with regional physicians, nurses, certified research assistants and research bases to provide a wide range of cancer research protocols locally. 4) Maintain a consortium of quality institutions and physician investigators committed to further cancer treatment and control through research. 5) Expand access to state of the art treatment and cancer control studies to the underserved populations of our service. 6) Expand the scope of the CICCOP into other Illinois communities while guarding the highest quality of research. 7) Expand access to cancer research protocols to persons living in underserved areas in Illinois by recruiting new investigators into the CICCOP from these areas while continuing to maintain the quality and integrity of cancer treatment and control clinical trials 8) Involve a wide range of specialty and primary care physicians from the CICCOP service area in cancer control protocols. 9) Ensure quality data management services to CICCOP physician investigators, research bases and NCI. 1) Maintain and enhance quality assurances procedures, physician participation policies, pharmacy regulatory requirement and protocol selection methods. 11) Comply with NCI reporting requirements in an accurate and timely manner. A small core of highly productive oncologists, a network of certified research associates (CRAs), the Central Office and very strong hospital support enables the CICCOP to meet its obligations to the NCI and to its communities by far exceeding CCOP program minimums. Between 2000 and 2005, the CCOP projects it will average 400 credits annually from treatment, cancer control and follow-up credits.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045807-17
Application #
6512595
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J1))
Program Officer
Minasian, Lori M
Project Start
1987-08-15
Project End
2005-05-31
Budget Start
2002-06-25
Budget End
2003-05-31
Support Year
17
Fiscal Year
2002
Total Cost
$1,308,125
Indirect Cost
Name
Decatur Memorial Hospital
Department
Type
DUNS #
046584991
City
Decatur
State
IL
Country
United States
Zip Code
62526
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 59 publications